Last €38.03 EUR
Change Today -0.13 / -0.34%
Volume 47.2K
DBV On Other Exchanges
Symbol
Exchange
EN Paris
NASDAQ GS
Frankfurt
As of 11:35 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Open
€38.45
Previous Close
€38.16
Day High
€38.48
Day Low
€37.65
52 Week High
01/2/15 - €47.23
52 Week Low
05/2/14 - €14.61
Market Cap
730.5M
Average Volume 10 Days
71.3K
EPS TTM
€-1.42
Shares Outstanding
19.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.

48 Employees
Last Reported Date: 10/22/14
Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €280.0K
Compensation as of Fiscal Year 2013.

dbv technologies sa (DBV) Key Developments

DBV Technologies Appoints J-P Moreau to its Scientific Advisory Board

DBV Technologies announced the appointment of Dr. Jacques-Pierre Moreau to its Scientific Advisory Board. Dr. Moreau brings to DBV his unique expertise and knowledge across a wide range of disease areas and will contribute in defining aggressive approaches to potentially extend the use of epicutaneous immunotherapy (EPIT) and Viaskin technology to a wide range of therapeutic opportunities. Moreau has broad industry experience across the spectrum of drug discovery, development and commercialization. He has been founder or co-founder of successful biotechs such as Biomeasure Inc. (MA, U.S.A.), Kinerton Ltd. (Ireland), ProteoThera (MA, U.S.A.) and Mulleris Therapeutics (MA, U.S.A.). Dr. Moreau is the former Chief Scientific Officer and Executive Vice-President for Ipsen SA (France). Active contributor to Ipsen's IPO in 2005 and to the spin-offs of Preglem (CH), Radius Health Inc. (MA, U.S.A.), Functional Therapeutics (U.K./CH) and Rhythm Pharmaceuticals (MA, U.S.A.). Dr. Moreau is a Director of Dr. Reddy's Laboratories Ltd. (India), member of the Science, Technology, Strategy and Risk committees. He is also former board member of Phytochemics, an Inventage Venture-funded company, former advisor for Nitto Denko & Teijin Pharmaceutical (Japan) and current advisor for Genosys (U.S.A.), and Banque Oddo (France).

DBV Technologies S.A. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:50 PM

DBV Technologies S.A. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:50 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Charles Ruban, Chief Development Officer, Senior Executive Vice President of Clinical Development & North American Operations and Member of Operations Committee, David Schilansky, Chief Operating Officer.

DBV Technologies S.A. Announces Earnings Results for the Full Year Ended December 31, 2014

DBV Technologies S.A. announced earnings results for the full year ended December 31, 2014. For the full year 2014, the total income reached EUR 4.8 million, up from EUR 3.8 million for the same period in 2013. This increase primarily resulted from an increase in Research Tax Credit amounting to EUR 4.3 million over the period, compared to EUR 3.3 million a year earlier.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €38.03 EUR -0.13

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr750.00 DKK -3.00
Allergy Therapeutics PLC 25.50 GBp 0.00
Merck & Co Inc $58.56 USD +0.215
Sanofi €87.45 EUR +1.29
Stallergenes SA €54.00 EUR -4.10
View Industry Companies
 

Industry Analysis

DBV

Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 94.7x
Price/Book 15.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 113.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit www.dbv-technologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.